Table 3.
Outcomes (values are expressed as mean and standard deviation).
| Baseline | Postexercise | ||
|---|---|---|---|
| VO2 max relative (l/kg·min) | Placebo PBMT Active PBMT |
— | 55.69 (±5.55) 59.40 (±5.08)a |
| VO2 max absolute (l/min) | Placebo PBMT Active PBMT |
— | 3.57 (±0.60) 4.02 (±0.41)a |
| Time until exhaustion (s) | Placebo PBMT Active PBMT |
— | 504.59 (±160.44) 563.27 (±159.46)a |
| Anaerobic threshold (s) | Placebo PBMT Active PBMT |
— | 384.86 (±63.53) 440.73 (±58.58)a |
| Anaerobic threshold (l/min) | Placebo PBMT Active PBMT |
— | 2.93 (±0.46) 3.26 (±0.40)b |
| Aerobic threshold (s) | Placebo PBMT Active PBMT |
— | 169.73 (±45.40) 184.36 (±44.84) |
| Aerobic threshold (l/min) | Placebo PBMT Active PBMT |
— | 2.20 (±0.43) 2.53 (±0.29)a |
| CK (U·l−1) | Placebo PBMT Active PBMT |
201.76 (±32.98) 215.61 (±37.22) |
372.43 (±29.11) 282.03 (±33.26)c |
| LDH (U·l−1) | Placebo PBMT Active PBMT |
290.02 (±41.82) 302.13 (±46.73) |
483.55 (±38.09) 378.97 (±41.52)c |
| IL-1β (pg/ml) | Placebo PBMT Active PBMT |
2.98 (±0.56) 3.19 (±0.62) |
3.37 (±0.61) 3.40 (±0.54) |
| IL-6 (pg/ml) | Placebo PBMT Active PBMT |
33.92 (±6.09) 30.6 (±5.89) |
54.08 (±5.56) 42.77 (±6.01)c |
| TNF-α (pg/ml) | Placebo PBMT Active PBMT |
57.81 (±8.75) 60.04 (±9.03) |
63.99 (±9.87) 65.34 (10.71) |
| TBARS (nmol/ml) | Placebo PBMT Active PBMT |
3.42 (±0.85) 3.71 (±0.79) |
5.74 (±0.78) 3.94 (±0.71)c |
| Carbonylated proteins (nmol of DNPH/g/dl of protein) | Placebo PBMT Active PBMT |
2.07 (±0.67) 2.00 (±0.63) |
2.98 (±0.70) 2.34 (±0.59)a |
| SOD (U SOD/g of protein) | Placebo PBMT Active PBMT |
2.98 (±0.65) 2.82 (±0.55) |
1.99 (±0.86) 3.23 (±0.91)c |
| CAT (U CAT/g of protein) | Placebo PBMT Active PBMT |
2.81 (±0.73) 2.73 (±0.66) |
2.04 (±0.75) 3.24 (±0.83)c |
aDifference of placebo PBMT (p < 0.01). bDifference of placebo PBMT (p < 0.05). cDifference of placebo PBMT (p < 0.0001).